Evidence map›Paper›PMID 40881644›Full record

ArticleInternational journal of endocrinology2025

Astaxanthin Modulates Inflammation in Type 2 Diabetes via Regulation of microRNAs, Lysophosphatidylcholine, and α-Hydroxybutyrate.

Ali Sharifi-Rigi, Fatemeh Zal, Mohammad-Hossein Aarabi, Mehdi Dehghani, Nikoo Roustaei Rad, Sana Taghiyar

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Ali Sharifi-RigiStudent Research Committee, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0009-0001-1313-2681
Fatemeh ZalDepartment of Biochemistry, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.ORCID https://orcid.org/0000-0002-7078-4854
Mohammad-Hossein AarabiDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0001-6514-4492
Mehdi DehghaniConsultative Genomix, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-5258-1674
Nikoo Roustaei RadDepartment of Clinical Biochemistry, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.ORCID https://orcid.org/0000-0001-9289-6665
Sana TaghiyarDepartment of Clinical Biochemistry, International Campus, Shahid Sadoughi University of Medical Science, Yazd, Iran.ORCID https://orcid.org/0000-0003-0121-8696

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astaxanthin is a carotenoid compound that has several beneficial qualities, including antioxidant, anti-inflammatory, antiapoptotic, and antidiabetic effects. This study examined the effects of astaxanthin supplementation on inflammation-related microRNAs, lysophosphatidylcholine, and α-hydroxybutyrate in individuals with Type 2 diabetes. Fifty people with Type 2 diabetes volunteered in a placebo-controlled, randomized, double-blind clinical trial. Subjects were randomly determined to consume either 10 mg of astaxanthin (

Indexed as

astaxanthininflammationlysophosphatidylcholinemiRNAsType 2 diabetesα-hydroxybutyrate

Identifiers

PMID40881644
PMCPMC12390588

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.